Skip to content

Study · Observational study · 2025

6 results

The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study.

Yao S, Huang Q, Zou Y, Liu T, Yang Y, Huang T, Zhao Y, Dong X

Scientific reports22 Apr 2025Cited by 2 (Europe PMC)

PMID40263352 (opens in a new tab)PMCIDPMC12015295 (opens in a new tab)DOI10.1038/s41598-025-97160-7 (opens in a new tab)PepBankPUB-40263352
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In unresectable hepatocellular carcinoma, adding Tα1 to lenvatinib plus sintilimab gave a longer median overall survival (16 vs 11 months).

    In plain wordsIn patients with liver cancer, adding thymosin alpha‑1 to lenvatinib and sintilimab was linked to longer survival than the two drugs alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMedian overall survival
    Study

    n: not reported in source

    Comparator
    Lenvatinib plus sintilimab
    Analysis
    Primary
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    Median OS
    16 months
    with Tα1
    Median OS
    11 months
    control

    Source sentences

    Summary
    The experimental group had a longer median overall survival than the control group (16 months vs. 11 months, P = 0.018).
    2 context sentences
    Summary · context
    Patients with unresectable hepatocellular carcinoma treated with lenvatinib plus sintilimab at the People's Hospital of Guangxi Zhuang Autonomous Region from January 2020 to June 2022 were retrospectively analyzed.
    Summary · context
    The patients were divided into an experimental group and a control group based on their therapeutic regimens: thymosin α-1 plus lenvatinib and sintilimab (experimental group), and lenvatinib plus sintilimab (control group).
  2. 02HumanObservational studyEfficacy outcome

    In unresectable hepatocellular carcinoma, adding Tα1 to lenvatinib plus sintilimab gave a longer median progression-free survival (7 vs 4 months).

    In plain wordsIn patients with liver cancer, adding thymosin alpha‑1 to lenvatinib and sintilimab was linked to longer time without progression than the two drugs alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMedian progression-free survival
    Study

    n: not reported in source

    Comparator
    Lenvatinib plus sintilimab
    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Median PFS
    7 months
    with Tα1
    Median PFS
    4 months
    control

    Source sentences

    Summary
    The experimental group had a longer median progression-free survival than the control group (7 months vs. 4 months, P = 0.006).
    2 context sentences
    Summary · context
    Patients with unresectable hepatocellular carcinoma treated with lenvatinib plus sintilimab at the People's Hospital of Guangxi Zhuang Autonomous Region from January 2020 to June 2022 were retrospectively analyzed.
    Summary · context
    The patients were divided into an experimental group and a control group based on their therapeutic regimens: thymosin α-1 plus lenvatinib and sintilimab (experimental group), and lenvatinib plus sintilimab (control group).
  3. 03HumanObservational studyEfficacy outcome

    In unresectable hepatocellular carcinoma, the objective response rate was higher with added Tα1 (55.8%) than without (34.7%).

    In plain wordsIn patients with liver cancer, more tumors responded when thymosin alpha‑1 was added to lenvatinib and sintilimab (55.8% vs 34.7%).

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseObjective response rate
    Study

    n: not reported in source

    Comparator
    Lenvatinib plus sintilimab
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Objective response rate
    55.8%
    with Tα1
    Objective response rate
    34.7%
    control

    Source sentences

    Summary
    The objective response rate of the experimental group was 55.8% (24/43), and of the control group's 34.7% (17/49) (P = 0.042).
    2 context sentences
    Summary · context
    Patients with unresectable hepatocellular carcinoma treated with lenvatinib plus sintilimab at the People's Hospital of Guangxi Zhuang Autonomous Region from January 2020 to June 2022 were retrospectively analyzed.
    Summary · context
    The patients were divided into an experimental group and a control group based on their therapeutic regimens: thymosin α-1 plus lenvatinib and sintilimab (experimental group), and lenvatinib plus sintilimab (control group).
  4. 04HumanObservational studyEfficacy outcome

    In unresectable hepatocellular carcinoma, the disease control rate with added Tα1 (76.7%) was not significantly different from control (59.2%).

    In plain wordsIn patients with liver cancer, disease control with added thymosin alpha‑1 (76.7%) was not clearly different from the two drugs alone (59.2%).

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeDisease control rate
    Study

    n: not reported in source

    Comparator
    Lenvatinib plus sintilimab
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Disease control rate
    76.7%
    with Tα1
    Disease control rate
    59.2%
    control

    Source sentences

    Summary
    The disease control rate of the experimental group was 76.7% (33/43), while the control group had a rate of 59.2% (29/49) (P = 0.073).
    2 context sentences
    Summary · context
    Patients with unresectable hepatocellular carcinoma treated with lenvatinib plus sintilimab at the People's Hospital of Guangxi Zhuang Autonomous Region from January 2020 to June 2022 were retrospectively analyzed.
    Summary · context
    The patients were divided into an experimental group and a control group based on their therapeutic regimens: thymosin α-1 plus lenvatinib and sintilimab (experimental group), and lenvatinib plus sintilimab (control group).
  5. 05HumanObservational studySafety outcome

    In unresectable hepatocellular carcinoma, the incidence of grade 1-2 adverse events did not differ significantly between groups.

    In plain wordsIn patients with liver cancer, mild side effects were similar with and without thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeGrade 1-2 adverse events
    Study

    n: not reported in source

    Comparator
    Lenvatinib plus sintilimab
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no significant difference in the incidence of grade 1-2 adverse events or grade 3-4 adverse events between the two groups (P > 0.05).
    2 context sentences
    Summary · context
    Patients with unresectable hepatocellular carcinoma treated with lenvatinib plus sintilimab at the People's Hospital of Guangxi Zhuang Autonomous Region from January 2020 to June 2022 were retrospectively analyzed.
    Summary · context
    The patients were divided into an experimental group and a control group based on their therapeutic regimens: thymosin α-1 plus lenvatinib and sintilimab (experimental group), and lenvatinib plus sintilimab (control group).
  6. 06HumanObservational studySafety outcome

    In unresectable hepatocellular carcinoma, the incidence of grade 3-4 adverse events did not differ significantly between groups.

    In plain wordsIn patients with liver cancer, severe side effects were similar with and without thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeGrade 3-4 adverse events
    Study

    n: not reported in source

    Comparator
    Lenvatinib plus sintilimab
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no significant difference in the incidence of grade 1-2 adverse events or grade 3-4 adverse events between the two groups (P > 0.05).
    2 context sentences
    Summary · context
    Patients with unresectable hepatocellular carcinoma treated with lenvatinib plus sintilimab at the People's Hospital of Guangxi Zhuang Autonomous Region from January 2020 to June 2022 were retrospectively analyzed.
    Summary · context
    The patients were divided into an experimental group and a control group based on their therapeutic regimens: thymosin α-1 plus lenvatinib and sintilimab (experimental group), and lenvatinib plus sintilimab (control group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.